Jennifer A. Spinella

Renova Therapeutics, Inc. operates as a biopharmaceutical company. The firm is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. Its product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in patients with CHF. The company was founded by Jack W. Reich, H. Kirk Hammond and Craig Andrews in 2009 and is headquartered in San Diego, CA.